Now showing items 1-20 of 304

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03)
      <h4>Background</h4>Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)
      <h4>Background</h4>The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending ...
    • ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. 

      Sava, GP; Fan, H; Fisher, RA; Lusvarghi, S; Pancholi, S; Ambudkar, SV; Martin, L-A; Charles Coombes, R; Buluwela, L; Ali, S (2020-01)
      The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become ...
    • Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. 

      Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; Nikitorowicz-Buniak, J; Johnston, SR; Dowsett, M; Martin, L-A (2018-08)
      <h4>Background</h4>Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80-90% of ...
    • Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast. 

      Naidoo, K; Beardsley, B; Carder, PJ; Deb, R; Fish, D; Girling, A; Hales, S; Howe, M; Wastall, LM; Lane, S; Lee, AHS; Philippidou, M; Quinn, C; Stephenson, T; Pinder, SE (2016-12)
      Although the UK National Institute for Health and Care Excellence guidelines recommend that in patients with biopsy-proven invasive lobular carcinoma (ILC), preoperative MRI scan is considered, the accuracy of diagnosis ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. 

      Schmidt, MK; Hogervorst, F; van Hien, R; Cornelissen, S; Broeks, A; Adank, MA; Meijers, H; Waisfisz, Q; Hollestelle, A; Schutte, M; van den Ouweland, A; Hooning, M; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Arndt, V; Bermisheva, M; Bogdanova, NV; Bolla, MK; Brauch, H; Brenner, H; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dunning, AM; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Haeberle, L; Hall, P; Hillemanns, P; Hopper, JL; Jakubowska, A; John, EM; Jones, M; Khusnutdinova, E; Knight, JA; Kosma, V-M; Kristensen, V; Lee, A; Lindblom, A; Lubinski, J; Mannermaa, A; Margolin, S; Meindl, A; Milne, RL; Muranen, TA; Newcomb, PA; Offit, K; Park-Simon, T-W; Peto, J; Pharoah, PDP; Robson, M; Rudolph, A; Sawyer, EJ; Schmutzler, RK; Seynaeve, C; Soens, J; Southey, MC; Spurdle, AB; Surowy, H; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Trentham-Dietz, A; Vachon, C; Wang, Q; Whittemore, AS; Ziogas, A; van der Kolk, L; Nevanlinna, H; Dörk, T; Bojesen, S; Easton, DF (2016-08)
      <h4>Purpose</h4>CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits ...
    • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. 

      Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; Neven, P; Park, YH; Prat, A; Bachelot, T; Juric, D; Turner, N; Sophos, N; Zarate, JP; Arce, C; Shen, Y-M; Turner, S; Kanakamedala, H; Hsu, W-C; Chia, S
      <h4>Background</h4>Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are ...
    • Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. 

      Trabert, B; Poole, EM; White, E; Visvanathan, K; Adami, H-O; Anderson, GL; Brasky, TM; Brinton, LA; Fortner, RT; Gaudet, M; Hartge, P; Hoffman-Bolton, J; Jones, M; Lacey, JV; Larsson, SC; Mackenzie, GG; Schouten, LJ; Sandler, DP; O'Brien, K; Patel, AV; Peters, U; Prizment, A; Robien, K; Setiawan, VW; Swerdlow, A; van den Brandt, PA; Weiderpass, E; Wilkens, LR; Wolk, A; Wentzensen, N; Tworoger, SS; Ovarian Cancer Cohort Consortium (OC3) (2019-02)
      BACKGROUND:Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily ...
    • Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. 

      Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; Bane, AL; Bartlett, JMS; Borgquist, S; Chang, MC; Dodson, A; Ehinger, A; Fineberg, S; Focke, CM; Gao, D; Gown, AM; Gutierrez, C; Hugh, JC; Kos, Z; Laenkholm, A-V; Mastropasqua, MG; Moriya, T; Nofech-Mozes, S; Osborne, CK; Penault-Llorca, FM; Piper, T; Sakatani, T; Salgado, R; Starczynski, J; Sugie, T; van der Vegt, B; Viale, G; Hayes, DF; McShane, LM; Dowsett, M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) (2019-08)
      <h4>Aims</h4>The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      <h4>Background</h4>The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Association analysis identifies 65 new breast cancer risk loci. 

      Michailidou, K; Lindström, S; Dennis, J; Beesley, J; Hui, S; Kar, S; Lemaçon, A; Soucy, P; Glubb, D; Rostamianfar, A; Bolla, MK; Wang, Q; Tyrer, J; Dicks, E; Lee, A; Wang, Z; Allen, J; Keeman, R; Eilber, U; French, JD; Qing Chen, X; Fachal, L; McCue, K; McCart Reed, AE; Ghoussaini, M; Carroll, JS; Jiang, X; Finucane, H; Adams, M; Adank, MA; Ahsan, H; Aittomäki, K; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Arun, B; Auer, PL; Bacot, F; Barrdahl, M; Baynes, C; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bernstein, L; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bonanni, B; Børresen-Dale, A-L; Brand, JS; Brauch, H; Brennan, P; Brenner, H; Brinton, L; Broberg, P; Brock, IW; Broeks, A; Brooks-Wilson, A; Brucker, SY; Brüning, T; Burwinkel, B; Butterbach, K; Cai, Q; Cai, H; Caldés, T; Canzian, F; Carracedo, A; Carter, BD; Castelao, JE; Chan, TL; David Cheng, T-Y; Seng Chia, K; Choi, J-Y; Christiansen, H; Clarke, CL; NBCS Collaborators; Collée, M; Conroy, DM; Cordina-Duverger, E; Cornelissen, S; Cox, DG; Cox, A; Cross, SS; Cunningham, JM; Czene, K; Daly, MB; Devilee, P; Doheny, KF; Dörk, T; Dos-Santos-Silva, I; Dumont, M; Durcan, L; Dwek, M; Eccles, DM; Ekici, AB; Eliassen, AH; Ellberg, C; Elvira, M; Engel, C; Eriksson, M; Fasching, PA; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Fritschi, L; Gaborieau, V; Gabrielson, M; Gago-Dominguez, M; Gao, Y-T; Gapstur, SM; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Glendon, G; Goldberg, MS; Goldgar, DE; González-Neira, A; Grenaker Alnæs, GI; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hamel, N; Hankinson, S; Harrington, P; Hart, SN; Hartikainen, JM; Hartman, M; Hein, A; Heyworth, J; Hicks, B; Hillemanns, P; Ho, DN; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Hou, M-F; Hsiung, C-N; Huang, G; Humphreys, K; Ishiguro, J; Ito, H; Iwasaki, M; Iwata, H; Jakubowska, A; Janni, W; John, EM; Johnson, N; Jones, K; Jones, M; Jukkola-Vuorinen, A; Kaaks, R; Kabisch, M; Kaczmarek, K; Kang, D; Kasuga, Y; Kerin, MJ; Khan, S; Khusnutdinova, E; Kiiski, JI; Kim, S-W; Knight, JA; Kosma, V-M; Kristensen, VN; Krüger, U; Kwong, A; Lambrechts, D; Le Marchand, L; Lee, E; Lee, MH; Lee, JW; Neng Lee, C; Lejbkowicz, F; Li, J; Lilyquist, J; Lindblom, A; Lissowska, J; Lo, W-Y; Loibl, S; Long, J; Lophatananon, A; Lubinski, J; Luccarini, C; Lux, MP; Ma, ESK; MacInnis, RJ; Maishman, T; Makalic, E; Malone, KE; Kostovska, IM; Mannermaa, A; Manoukian, S; Manson, JE; Margolin, S; Mariapun, S; Martinez, ME; Matsuo, K; Mavroudis, D; McKay, J; McLean, C; Meijers-Heijboer, H; Meindl, A; Menéndez, P; Menon, U; Meyer, J; Miao, H; Miller, N; Taib, NAM; Muir, K; Mulligan, AM; Mulot, C; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, SF; Noh, D-Y; Nordestgaard, BG; Norman, A; Olopade, OI; Olson, JE; Olsson, H; Olswold, C; Orr, N; Pankratz, VS; Park, SK; Park-Simon, T-W; Lloyd, R; Perez, JIA; Peterlongo, P; Peto, J; Phillips, K-A; Pinchev, M; Plaseska-Karanfilska, D; Prentice, R; Presneau, N; Prokofyeva, D; Pugh, E; Pylkäs, K; Rack, B; Radice, P; Rahman, N; Rennert, G; Rennert, HS; Rhenius, V; Romero, A; Romm, J; Ruddy, KJ; Rüdiger, T; Rudolph, A; Ruebner, M; Rutgers, EJT; Saloustros, E; Sandler, DP; Sangrajrang, S; Sawyer, EJ; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schumacher, F; Schürmann, P; Scott, RJ; Scott, C; Seal, S; Seynaeve, C; Shah, M; Sharma, P; Shen, C-Y; Sheng, G; Sherman, ME; Shrubsole, MJ; Shu, X-O; Smeets, A; Sohn, C; Southey, MC; Spinelli, JJ; Stegmaier, C; Stewart-Brown, S; Stone, J; Stram, DO; Surowy, H; Swerdlow, A; Tamimi, R; Taylor, JA; Tengström, M; Teo, SH; Beth Terry, M; Tessier, DC; Thanasitthichai, S; Thöne, K; Tollenaar, RAEM; Tomlinson, I; Tong, L; Torres, D; Truong, T; Tseng, C-C; Tsugane, S; Ulmer, H-U; Ursin, G; Untch, M; Vachon, C; van Asperen, CJ; Van Den Berg, D; van den Ouweland, AMW; van der Kolk, L; van der Luijt, RB; Vincent, D; Vollenweider, J; Waisfisz, Q; Wang-Gohrke, S; Weinberg, CR; Wendt, C; Whittemore, AS; Wildiers, H; Willett, W; Winqvist, R; Wolk, A; Wu, AH; Xia, L; Yamaji, T; Yang, XR; Har Yip, C; Yoo, K-Y; Yu, J-C; Zheng, W; Zheng, Y; Zhu, B; Ziogas, A; Ziv, E; ABCTB Investigators; ConFab/AOCS Investigators; Lakhani, SR; Antoniou, AC; Droit, A; Andrulis, IL; Amos, CI; Couch, FJ; Pharoah, PDP; Chang-Claude, J; Hall, P; Hunter, DJ; Milne, RL; García-Closas, M; Schmidt, MK; Chanock, SJ; Dunning, AM; Edwards, SL; Bader, GD; Chenevix-Trench, G; Simard, J; Kraft, P; Easton, DF (2017-11)
      Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      <h4>Importance</h4>The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. 

      Hamdi, Y; Soucy, P; Adoue, V; Michailidou, K; Canisius, S; Lemaçon, A; Droit, A; Andrulis, IL; Anton-Culver, H; Arndt, V; Baynes, C; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borresen-Dale, A-L; Brand, JS; Brauch, H; Brenner, H; Broeks, A; Burwinkel, B; Chang-Claude, J; NBCS Collaborators; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Devilee, P; Dörk, T; Dos-Santos-Silva, I; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; García-Closas, M; Giles, GG; Goldberg, MS; González-Neira, A; Grenaker-Alnæs, G; Guénel, P; Haeberle, L; Haiman, CA; Hamann, U; Hallberg, E; Hooning, MJ; Hopper, JL; Jakubowska, A; Jones, M; Kabisch, M; Kataja, V; Lambrechts, D; Le Marchand, L; Lindblom, A; Lubinski, J; Mannermaa, A; Maranian, M; Margolin, S; Marme, F; Milne, RL; Neuhausen, SL; Nevanlinna, H; Neven, P; Olswold, C; Peto, J; Plaseska-Karanfilska, D; Pylkäs, K; Radice, P; Rudolph, A; Sawyer, EJ; Schmidt, MK; Shu, X-O; Southey, MC; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Van Den Ouweland, AMW; Wang, Q; Winqvist, R; kConFab/AOCS Investigators; Zheng, W; Benitez, J; Chenevix-Trench, G; Dunning, AM; Pharoah, PDP; Kristensen, V; Hall, P; Easton, DF; Pastinen, T; Nord, S; Simard, J (2016-12)
      There are significant inter-individual differences in the levels of gene expression. Through modulation of gene expression, cis-acting variants represent an important source of phenotypic variation. Consequently, cis-regulatory ...
    • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. 

      Zhao, Z; Wen, W; Michailidou, K; Bolla, MK; Wang, Q; Zhang, B; Long, J; Shu, X-O; Schmidt, MK; Milne, RL; García-Closas, M; Chang-Claude, J; Lindstrom, S; Bojesen, SE; Ahsan, H; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Blomqvist, C; Bogdanova, NV; Børresen-Dale, A-L; Brand, J; Brauch, H; Brenner, H; Burwinkel, B; Cai, Q; Casey, G; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dörk, T; Dumont, M; Fasching, PA; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Fostira, F; Gammon, M; Giles, GG; Guénel, P; Haiman, CA; Hamann, U; Harrington, P; Hartman, M; Hooning, MJ; Hopper, JL; Jakubowska, A; Jasmine, F; John, EM; Johnson, N; Kabisch, M; Khan, S; Kibriya, M; Knight, JA; Kosma, V-M; Kriege, M; Kristensen, V; Le Marchand, L; Lee, E; Li, J; Lindblom, A; Lophatananon, A; Luben, R; Lubinski, J; Malone, KE; Mannermaa, A; Manoukian, S; Margolin, S; Marme, F; McLean, C; Meijers-Heijboer, H; Meindl, A; Miao, H; Muir, K; Neuhausen, SL; Nevanlinna, H; Neven, P; Olson, JE; Perkins, B; Peterlongo, P; Phillips, K-A; Pylkäs, K; Rudolph, A; Santella, R; Sawyer, EJ; Schmutzler, RK; Schoemaker, M; Shah, M; Shrubsole, M; Southey, MC; Swerdlow, AJ; Toland, AE; Tomlinson, I; Torres, D; Truong, T; Ursin, G; Van Der Luijt, RB; Verhoef, S; Wang-Gohrke, S; Whittemore, AS; Winqvist, R; Pilar Zamora, M; Zhao, H; Dunning, AM; Simard, J; Hall, P; Kraft, P; Pharoah, P; Hunter, D; Easton, DF; Zheng, W (2016-05)
      <h4>Purpose</h4>Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors.<h4>Methods</h4>We constructed ...
    • Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. 

      Rambau, PF; Vierkant, RA; Intermaggio, MP; Kelemen, LE; Goodman, MT; Herpel, E; Pharoah, PD; Kommoss, S; Jimenez-Linan, M; Karlan, BY; Gentry-Maharaj, A; Menon, U; Polo, SH; Candido Dos Reis, FJ; Doherty, JA; Gayther, SA; Sharma, R; Larson, MC; Harnett, PR; Hatfield, E; de Andrade, JM; Nelson, GS; Steed, H; Schildkraut, JM; Carney, ME; Høgdall, E; Whittemore, AS; Widschwendter, M; Kennedy, CJ; Wang, F; Wang, Q; Wang, C; Armasu, SM; Daley, F; Coulson, P; Jones, ME; Anglesio, MS; Chow, C; de Fazio, A; García-Closas, M; Brucker, SY; Cybulski, C; Harris, HR; Hartkopf, AD; Huzarski, T; Jensen, A; Lubiński, J; Oszurek, O; Benitez, J; Mina, F; Staebler, A; Taran, FA; Pasternak, J; Talhouk, A; Rossing, MA; Hendley, J; AOCS Group; Edwards, RP; Fereday, S; Modugno, F; Ness, RB; Sieh, W; El-Bahrawy, MA; Winham, SJ; Lester, J; Kjaer, SK; Gronwald, J; Sinn, P; Fasching, PA; Chang-Claude, J; Moysich, KB; Bowtell, DD; Hernandez, BY; Luk, H; Behrens, S; Shah, M; Jung, A; Ghatage, P; Alsop, J; Alsop, K; García-Donas, J; Thompson, PJ; Swerdlow, AJ; Karpinskyj, C; Cazorla-Jiménez, A; García, MJ; Deen, S; Wilkens, LR; Palacios, J; Berchuck, A; Koziak, JM; Brenton, JD; Cook, LS; Goode, EL; Huntsman, DG; Ramus, SJ; Köbel, M (2018-10)
      We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. 

      Shu, X; Wu, L; Khankari, NK; Shu, X-O; Wang, TJ; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Milne, RL; Schmidt, MK; Pharoah, PDP; Andrulis, IL; Hunter, DJ; Simard, J; Easton, DF; Zheng, W; Breast Cancer Association Consortium (2019-06)
      <h4>Background</h4>In addition to the established association between general obesity and breast cancer risk, central obesity and circulating fasting insulin and glucose have been linked to the development of this common ...
    • ATR Is a Therapeutic Target in Synovial Sarcoma. 

      Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; Krastev, DB; Pemberton, HN; Campbell, J; Gulati, A; Elliott, R; Menon, M; Selfe, JL; Brough, R; Pettitt, SJ; Niedzwiedz, W; van der Graaf, WTA; Shipley, J; Ashworth, A; Lord, CJ (2017-12)
      Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ...